SenesTech, Inc.

NasdaqCM SNES

SenesTech, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2024: USD 1.65 M

SenesTech, Inc. Revenue is USD 1.65 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 38.16% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

SenesTech, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 1.20 M, a 34.12% change year over year.
SenesTech, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 891.00 K, a 85.62% change year over year.
SenesTech, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 480.00 K, a 92.77% change year over year.
SenesTech, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 249.00 K, a 15.28% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

NasdaqCM: SNES

SenesTech, Inc.

CEO	Mr. Joel L. Fruendt
IPO Date	Dec. 8, 2016
Location	United States
Headquarters	23460 North 19th Avenue
Employees	25
Sector	Health Care
Industries Biotechnology Agriculture Pharmaceuticals

Description

SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.

Key trends

Past 5 years